11. SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	On January 3, 2019, Dr. Kevin Schewe, CEO of the Company, advanced $2,000 pursuant to a convertible loan agreement and immediately converted the $2,000 loan into 26,143,791 shares of Company common stock at a conversion price of $0.0000765 per common share. On January 28, 2019, we issued 3,200,000 shares of our common stock to a consultant. The shares were issued at fair market value of approximately $1,000 on the date of the issuance. On February 12, 2019, we issued a Promissory Note to Viaspace California, Inc. whereby Viaspace California may borrow up to $100,000. Viaspace California will draw funds from the note as needed and will incur an interest of 10% per annum. The first draw occurred on February 12, 2019 in the amount of $15,000. The Note must be paid in full, including interest and any late fees, by February 12, 2021. On March 6, 2019, pursuant to a Business Sale Agreement, dated March 6, 2019, by Viaspace, Inc. and Bad Love Cosmetics Company, LLC, dba Elite Therapeutics (“Elite”), the Company completed its previously announced acquisition of Elite. The acquisition was made through an all stock purchase of 775,984,665 shares.

11. SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2018

On January 3, 2019, Dr. Kevin Schewe, CEO of the Company, advanced $2,000 pursuant to a convertible loan agreement and immediately converted the $2,000 loan into 26,143,791 shares of Company common stock at a conversion price of $0.0000765 per common share.

On January 28, 2019, we issued 3,200,000 shares of our common stock to a consultant. The shares were issued at fair market value of approximately $1,000 on the date of the issuance.

On February 12, 2019, we issued a Promissory Note to Viaspace California, Inc. whereby Viaspace California may borrow up to $100,000. Viaspace California will draw funds from the note as needed and will incur an interest of 10% per annum. The first draw occurred on February 12, 2019 in the amount of $15,000. The Note must be paid in full, including interest and any late fees, by February 12, 2021.

On March 6, 2019, pursuant to a Business Sale Agreement, dated March 6, 2019, by Viaspace, Inc. and Bad Love Cosmetics Company, LLC, dba Elite Therapeutics (“Elite”), the Company completed its previously announced acquisition of Elite. The acquisition was made through an all stock purchase of 775,984,665 shares.

VIASPACE Inc. 10-K